GlobeNewswire·Oct 8, 2026, 8:00 AM ET

Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value

Medicus Pharma Ltd. (NASDAQ: MDCX) celebrated its third anniversary with a strategic update focused on execution and capital-efficient drug development.
The company has transformed into a precision oncology-led biotechnology firm with a portfolio anchored by CD228V, SkinJect, and Teverelix.
Approximately $90 million was raised through equity and debt financing since October 2023 to support clinical development, strategic acquisitions, and operations.
CD228V is an investigational antibody-drug conjugate targeting melanotransferrin (CD228) using Pfizer's vedotin linker-payload platform, with initial development priority on melanoma.
SkinJect completed the SKNJCT-003 Phase 2 study, identifying a 200-microgram dose for the FDA-authorized registrational SKNJCT-005 study in Gorlin syndrome patients.
Teverelix, acquired via Antev in August 2025, is a next-generation GnRH antagonist being developed for acute urinary retention relapse prevention, symptomatic endometriosis, and advanced prostate cancer.
The company aims to advance clinical milestones, align organizational costs with priorities, and pursue licensing or co-development partnerships to reduce capital needs.
Medicus intends to demonstrate value through stronger clinical evidence, clearer development pathways, and strategic transactions that support continued advancement.